The global dry age-related macular degeneration market is likely to register a CAGR of over 7.1% with an incremental growth of USD 2 billion during the forecast period 2022-2028.

The report provides in-depth analysis and insights regarding the current global market scenario, latest trends and drivers into global dry age-related macular degeneration market. It offers an exclusive insight into various details such as market size, key trends, competitive landscape, growth rate and market segments. This study also provides an analysis of the impact of the COVID-19 crisis on the dry age-related macular degeneration industry.

This industry report offers market estimates and forecasts of the global market, followed by a detailed analysis of the category, stage, age group, route of administration, end user, and region. The global market for dry age-related macular degeneration can be segmented by category: diagnosis, treatment. Dry age-related macular degeneration market is further segmented by stage: early AMD, intermediate AMD, late AMD. Based on age group, the dry age-related macular degeneration market is segmented into: above 40 years, above 60 years, above 75 years. On the basis of route of administration, the dry age-related macular degeneration market also can be divided into: injectables, oral. Dry age-related macular degeneration market by end user is categorized into: academic research institutes, diagnostic centers, hospitals & clinics, others. The dry age-related macular degeneration market by region can be segmented into: North America, Asia Pacific, Europe, Rest of the World (ROW).

By category:
– diagnosis
– treatment

By stage:
– early AMD
– intermediate AMD
– late AMD

By age group:
– above 40 years
– above 60 years
– above 75 years

By route of administration:
– injectables
– oral

By end user:
– academic research institutes
– diagnostic centers
– hospitals & clinics
– others

By region:
– North America
– Asia Pacific
– Europe
– Rest of the World (ROW)

The market research report covers the analysis of key stake holders of the global dry age-related macular degeneration market. Some of the leading players profiled in the report include Alimera Sciences, Inc., Allergan plc (AbbVie Inc.), Bausch Health Companies Inc., Belite Bio, Inc, Eyestem Research Private Limited, IVERIC bio, Inc., Kubota Pharmaceutical Holdings Co., Ltd., Ocumension Therapeutics Ltd., Phio Pharmaceuticals Inc., Santen Pharmaceutical Co., Ltd., Stealth BioTherapeutics Corp., YUYANG DNU Co., Ltd., among others.
*REQUEST FREE SAMPLE TO GET A COMPLETE LIST OF COMPANIES

Historical & Forecast Period
This research report provides analysis for each segment from 2018 to 2028 considering 2021 to be the base year.

Scope of the Report
– To analyze and forecast the market size of the global dry age-related macular degeneration market.
– To classify and forecast the global dry age-related macular degeneration market based on category, stage, age group, route of administration, end user, region.
– To identify drivers and challenges for the global dry age-related macular degeneration market.
– To examine competitive developments such as mergers & acquisitions, agreements, collaborations and partnerships, etc., in the global dry age-related macular degeneration market.
– To identify and analyze the profile of leading players operating in the global dry age-related macular degeneration market.

Why Choose This Report
– Gain a reliable outlook of the global dry age-related macular degeneration market forecasts from 2022 to 2028 across scenarios.
– Identify growth segments for investment.
– Stay ahead of competitors through company profiles and market data.
– The market estimate for ease of analysis across scenarios in Excel format.
– Strategy consulting and research support for three months.
– Print authentication provided for the single-user license.